Zymeworks Inc. (ZYME) Fair Value 2026

ZYME · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.6 /10

32 fundamental signals · 3 models active

Value Trap Risk

SAFE (15/100)

Quick Summary — As of 2026-08-28, Zymeworks Inc. (ZYME) trades at $28.27, versus a $4.10 median fair value across its 3 active models — 85.5% below the current price. QOC: 6.6/10. Value Trap Risk: 15/100 (SAFE). 3/13 models active.

Key Facts

Ticker
ZYME
Price
$28.27
Quality Score
6.6/10
Value Trap Risk
15/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Zymeworks Inc. (ZYME) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Zymeworks Inc. (ZYME) appears overvalued as of : the median of 3 independent fair value estimates is $4.10, 85.5% below the current price of $28.27. Estimates range from $1.65 to $5.13. ZYME scores 6.6/10 on fundamental quality and 15/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ZYME’s -85.5% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Zymeworks Inc. Stock in 2026? →

What Fair Value Does Each Model Give ZYME?

3 Intrinsic Value Models vs. Current Price ($28.27)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $1.65 -94.2%
Relative · Medium Conviction
 $5.13 -81.8%
Relative · Low Conviction
 $4.10 -85.5%

All Models Active

All 3 models are displayed above.

What Is ZYME's Fair Value Range?

Spread across 3 independent models · $1.65 to $5.13

CirclFi's 3 active models place Zymeworks Inc. (ZYME) between $1.65 and $5.13 per share, a spread of 85% of the median. The median of that range — $4.10 — is the fair value CirclFi publishes for ZYME, against a current price of $28.27.

Low · First ChicagoHigh · Regime Cross
$1.65median $4.10$5.13
Where the range comes from
Most bearish modelFirst Chicago$1.65
Most bullish modelRegime Cross-Sectional$5.13
Model agreement0 bullish · 3 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on ZYME, not a CirclFi price target. How each model works →

What Is Zymeworks Inc. (ZYME) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Zymeworks Inc.'s intrinsic value is estimated at $4.10, suggesting the stock is overvalued at its current price of $28.27. With 3 out of 3 models flagging downside (-85.5% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About ZYME?

3 of 13 models are currently active for ZYME. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for ZYME is $4.10 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ZYME Rank in Biotechnology?

Among 625 Biotechnology stocks, ZYME ranks #75 by Quality of Company score. CirclFi's QOC score of 6.6/10 evaluates 32 fundamental signals. A score of 6.6 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Zymeworks Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating ZYME should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ZYME a Value Trap?

CirclFi's Value Trap algorithm assigns ZYME a score of 15/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Zymeworks Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Zymeworks Inc.'s fundamental quality profile registers 6.6/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+12.3% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ZYME valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ZYME's 3 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Zymeworks Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MRKRMarker Therapeutics, Inc.QOC 6.7ABCLAbCellera Biologics Inc.QOC 6.6ZLABZai Lab LimitedQOC 6.7WVEWave Life Sciences, Inc.QOC 6.6FENCFennec Pharmaceuticals Inc.QOC 6.7NTRBNutriband Inc.QOC 6.6PRMEPrime Medicine, Inc.QOC 5.4TELOTelomir Pharmaceuticals, Inc.QOC 4.8RGBPRegen BioPharma, Inc.QOC 3.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MRKR · ABCL · ZLAB · WVE · FENC · NTRB · PRME · TELO · RGBP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ZYME?

7 companies across all industries closest to ZYME’s Quality of Company score of 6.6/10.

UNITUniti Group Inc.QOC 6.6CLARClarus CorporationQOC 6.6KOSSKoss CorporationQOC 6.6GTNGray Media, Inc.QOC 6.6INSEInspired Entertainment, Inc.QOC 6.6NCDLNuveen Churchill Direct Lending Corp.QOC 6.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: UNIT · CLAR · KOSS · GTN · INSE · NCDL · NVDA

Where Does ZYME Sit in CirclFi's Biotechnology Rankings?

ZYME is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Zymeworks Inc.’s Valuation?

What is Zymeworks Inc.'s intrinsic value in 2026?

CirclFi puts Zymeworks Inc. (ZYME)'s intrinsic value at $4.10 — the median of 3 independent model estimates as of 2026-08-28, ranging from $1.65 to $5.13. The Quality of Company score is 6.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ZYME overvalued or undervalued right now?

At $28.27, 0 of 3 active models suggest ZYME may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $4.10, 85.5% below the current price of $28.27 — a consensus view that ZYME is overvalued. The assessment depends on which methodology best fits Zymeworks Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.6 mean for ZYME?

Zymeworks Inc.'s QOC of 6.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ZYME?

CirclFi analyzes ZYME with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ZYME?

Of the 3 models currently active on ZYME, Regime Cross-Sectional is the most bullish at $5.13 per share, and First Chicago is the most bearish at $1.65. CirclFi's published fair value for ZYME is the median of that range, $4.10, not either extreme. The gap between the two ends equals 85% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is ZYME a value trap in 2026?

Zymeworks Inc.'s Value Trap score is 15/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Zymeworks Inc. (ZYME) has a median fair value of $4.10 — 85.5% below the current price of $28.27 — as of 2026-08-28.” Source: circlfi.com/stock/ZYME/ · Methodology
Primary sources for this ZYME valuation
  • Financial statements: Zymeworks Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001937653) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ZYME as of ; valuations recomputed .